Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
Cerubidin 20 mg Powder for Concentrate for Solution for Infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for Solution for Infusion. A microcrystalline, orange-red, sterile powder. |
Daunorubicin Hydrochloride equivalent to Daunorubicin 20 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Daunorubicin |
Daunorubicin is an anthracycline glycoside antibiotic and is a potent antileukaemic agent. It also has immunosuppressant effects. Daunorubicin may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction. |
| List of Excipients |
|---|
|
D-Mannitol |
Uncoloured Type III (Ph. Eur.) neutral glass vial fitted with butyl rubber stopper and aluminium overseal. The vials are available in packs of 1 or 10 vials.
Not all pack sizes may be marketed.
Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
PA0540/096/001
Date of first authorisation: 20 April 1995
Date of last renewal: 20 April 2010
| Drug | Countries | |
|---|---|---|
| CERUBIDIN | Ireland, Malta |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
